塞鲁美替尼
神经纤维瘤病
医学
冲刺
神经纤维瘤
物理疗法
儿科
癌症
内科学
病理
结直肠癌
克拉斯
作者
Andrea M. Gross,Colette Achée,Sarah E. Hart,Lindsay Brewer,Andrea Baldwin,Pamela L. Wolters,Brigitte C. Widemann
出处
期刊:Future Oncology
[Future Medicine]
日期:2024-02-22
卷期号:20 (14): 877-890
标识
DOI:10.2217/fon-2023-0565
摘要
This summary describes a publication about a study called SPRINT. The SPRINT study included 50 children with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) that could not be removed with surgery. PNs are tumors that grow along nerves and can cause various problems for children, such as pain, changes to appearance, and muscle weakness. In SPRINT, the study team wanted to learn whether a medication called selumetinib was able to shrink the PN caused by NF1 (also known as NF1-related PN), and if shrinking PNs helped relieve children of the problems caused by it. To assess how selumetinib might help, children had scans to measure the size of their PN, completed questionnaires, and had a variety of other tests done by their doctor. Their caregivers also completed questionnaires about their child. The children took selumetinib capsules twice a day on an empty stomach.
科研通智能强力驱动
Strongly Powered by AbleSci AI